← Leaderboards
Joshua Travers
University Of Colorado Denver
$340,378
Attributed
$340,378
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $106.9K · FY2019–24$200K$150K$100K$50K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$340,378 · 2
By mechanism
K99$213,842 · 1
F32$126,536 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Lori Sussel$26,422,962
- James V Degregori$21,700,379
- Mehdi Hedjazi Moghari$2,000,668
- Sally E Wenzel$36,525,494
- Rebecca Leanne Smathers McCullough$2,500,061
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingMyofibroblastFibroblastsLaboratoriesMentorshipMouse ModelClinically RelevantExtracellular MatrixGenesInnovationAttenuatedCardiacMolecularCardioprotectionCardiovascular DiseasesChromatinDepositionEpigenetic ProcessFoundationsFunctional DisorderGenetic TranscriptionHeart FailureCharacteristicsPathogenesis
Grant awards (4)
Elucidating the Molecular Mechanisms and Cellular Specificity of HDAC Inhibitor Efficacy in Diastolic Dysfunction$106,921
K99 · FY2024 · HL · contact PI
Elucidating the Molecular Mechanisms and Cellular Specificity of HDAC Inhibitor Efficacy in Diastolic Dysfunction$106,921
K99 · FY2023 · HL · contact PI
Exploring the Therapeutic Potential of BRD4 Extra-terminal Domain Inhibition in Cardiac Dysfunction and Remodeling. Fellow: Joshua Travers$65,310
F32 · FY2020 · HL · contact PI
Exploring the Therapeutic Potential of BRD4 Extra-terminal Domain Inhibition in Cardiac Dysfunction and Remodeling. Fellow: Joshua Travers$61,226
F32 · FY2019 · HL · contact PI